Want to see BNR full AI Analyst Report?
BNR Stock Chart & Stats
$23.40
<$0.01(0.06%)
At close: 4:00 PM EST
$23.40
<$0.01(0.06%)
Day’s Range― - ―
52-Week Range$5.02 - $41.72
Previous CloseN/A
Volume1.44K
Average Volume (3M)22.64K
Market Cap
$105.92M
Enterprise Value$112.09
Total Cash (Recent Filing)$446.00M
Total Debt (Recent Filing)$50.86M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-56.30
Shares Outstanding8,813,858
10 Day Avg. Volume13,298
30 Day Avg. Volume22,645
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.28
Price to Sales (P/S)0.28
P/FCF Ratio-4.51
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross Margins / Strong Unit EconomicsSustained gross margins near 75% indicate durable unit economics in NGS testing and lab services. High product-level profitability gives flexibility to invest in R&D, absorb reimbursement pressure, and drive operating leverage as volumes scale, supporting long-term margin sustainability.
Conservative Leverage And Solid LiquidityA low debt-to-equity ratio and substantial cash reserve provide financial flexibility to fund operations, partner programs, and periodic capex without urgent refinancing. This balance sheet conservatism reduces bankruptcy risk and supports multi-quarter execution of strategic transitions.
Improving Cash Burn And Operating Trajectory Vs Prior YearsThe company has meaningfully reduced cash burn from prior years, showing improved expense control and progress toward breakeven. Persistent negative cash flow remains, but the trend improvement is a durable positive for eventual self-funding and longer-term margin normalization if sustained.
Bears Say
Negative Operating And Free Cash FlowOngoing negative operating and free cash flow means the business is not yet self-sustaining and requires external liquidity for growth and operations. Over multiple quarters this constrains strategic optionality and makes long-term plans contingent on financing or sustained margin and volume improvement.
Uneven Top-line And Recent Revenue DeclinesDeclining revenue and uneven quarterly performance point to demand variability and execution/timing issues. For a diagnostics company, inconsistent volume trends hamper fixed-cost absorption, delay leverage benefits, and raise questions about sustainable market adoption of its test menu.
Revenue Mix Shift Raises Volatility & Execution RiskMoving away from steady central-lab revenues toward in-hospital and pharma R&D can improve margins but increases revenue lumpiness and execution complexity. Dependence on timing of trials, hospital adoption and partner contracts can produce multi-period volatility and greater operational risk for sustained growth.
Burning Rock Biotech News
BNR FAQ
What was Burning Rock Biotech Ltd.’s price range in the past 12 months?
Burning Rock Biotech Ltd. lowest stock price was $5.02 and its highest was $41.72 in the past 12 months.
What is Burning Rock Biotech Ltd.’s market cap?
Burning Rock Biotech Ltd.’s market cap is $105.92M.
When is Burning Rock Biotech Ltd.’s upcoming earnings report date?
Burning Rock Biotech Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 41 days.
How were Burning Rock Biotech Ltd.’s earnings last quarter?
Burning Rock Biotech Ltd. released its earnings results on Jun 09, 2026. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Burning Rock Biotech Ltd. overvalued?
According to Wall Street analysts Burning Rock Biotech Ltd.’s price is currently Overvalued.
Does Burning Rock Biotech Ltd. pay dividends?
Burning Rock Biotech Ltd. does not currently pay dividends.
What is Burning Rock Biotech Ltd.’s EPS estimate?
Burning Rock Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Burning Rock Biotech Ltd. have?
Burning Rock Biotech Ltd. has 8,813,858 shares outstanding.
What happened to Burning Rock Biotech Ltd.’s price movement after its last earnings report?
Burning Rock Biotech Ltd. reported an EPS of -$0.24 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.813%.
Which hedge fund is a major shareholder of Burning Rock Biotech Ltd.?
Currently, no hedge funds are holding shares in BNR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Burning Rock Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Insider Transactions
Bought Shares
Worth $6.2M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
176.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.25%
Trailing 12-Months
Company Description
Burning Rock Biotech Ltd.
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.